TIAA CREF Investment Management LLC increased its stake in shares of Kite Pharma, Inc. (NASDAQ:KITE) by 14.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 146,003 shares of the biopharmaceutical company’s stock after buying an additional 18,665 shares during the quarter. TIAA CREF Investment Management LLC owned 0.26% of Kite Pharma worth $15,136,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Kite Pharma by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company’s stock valued at $287,395,000 after purchasing an additional 507,289 shares during the last quarter. BlackRock Inc. raised its position in Kite Pharma by 106,272.1% in the 1st quarter. BlackRock Inc. now owns 3,621,971 shares of the biopharmaceutical company’s stock valued at $284,287,000 after purchasing an additional 3,618,566 shares during the last quarter. Point72 Asset Management L.P. raised its position in Kite Pharma by 235.0% in the 1st quarter. Point72 Asset Management L.P. now owns 819,900 shares of the biopharmaceutical company’s stock valued at $64,354,000 after purchasing an additional 575,178 shares during the last quarter. Columbia Wanger Asset Management LLC bought a new position in Kite Pharma in the 1st quarter valued at $35,452,000. Finally, Geode Capital Management LLC raised its position in Kite Pharma by 19.8% in the 1st quarter. Geode Capital Management LLC now owns 413,148 shares of the biopharmaceutical company’s stock valued at $32,427,000 after purchasing an additional 68,145 shares during the last quarter. Institutional investors and hedge funds own 87.72% of the company’s stock.

In other Kite Pharma news, Chairman Arie Belldegrun sold 26,347 shares of Kite Pharma stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $4,733,502.02. Following the transaction, the chairman now owns 135,507 shares of the company’s stock, valued at approximately $24,345,187.62. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jeffrey Wiezorek sold 10,000 shares of Kite Pharma stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $104.32, for a total transaction of $1,043,200.00. Following the transaction, the senior vice president now directly owns 31,071 shares in the company, valued at approximately $3,241,326.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 219,785 shares of company stock worth $28,366,420. Insiders own 14.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-has-15-14-million-position-in-kite-pharma-inc-kite/1600317.html.

Shares of Kite Pharma, Inc. (KITE) opened at 179.81 on Friday. Kite Pharma, Inc. has a 12-month low of $39.82 and a 12-month high of $179.87. The company’s market cap is $10.28 billion. The company’s 50-day moving average price is $148.92 and its 200 day moving average price is $102.00.

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.97) by $0.03. Kite Pharma had a negative return on equity of 59.56% and a negative net margin of 1,117.44%. The business had revenue of $10.10 million during the quarter, compared to the consensus estimate of $9.59 million. During the same quarter in the previous year, the business earned ($0.91) EPS. The company’s quarterly revenue was up 110.4% on a year-over-year basis. Equities analysts predict that Kite Pharma, Inc. will post ($8.23) earnings per share for the current year.

Several brokerages have issued reports on KITE. Canaccord Genuity downgraded Kite Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. Wedbush raised Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. SunTrust Banks, Inc. cut Kite Pharma from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Guggenheim cut Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 target price for the company. in a research note on Monday, August 28th. Finally, BTIG Research cut Kite Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, August 28th. Fourteen equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Kite Pharma has an average rating of “Hold” and an average target price of $92.64.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.